C4 Therapeutics appoints Ron Cooper as Chairman; Glenn Dubin resigns from board

C4 Therapeutics, Inc.

Ron Cooper appointed Chairman and director effective June 7, 2024, replacing Bruce Downey who remains a board member.
Director Glenn Dubin resigned effective same date; no disagreements with company.
Cooper granted stock options for 65,000 shares under 2020 Plan; one-third vests after one year, rest quarterly over two years.
Cooper brings experience as former CEO of Albireo (acquired by Ipsen) and nearly 30 years at Bristol-Myers Squibb.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Bruce Downey

Director

CCCC · C4 Therapeutics, Inc.

Effective: 2024-06-07
Successor: Ron Cooper
Filed: June 10, 2024, 7:59 PM ET

Bruce Downey resigned as Chair of the Board, but will continue to serve as a member of the Board

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Bruce Downey departed as Director at C4 Therapeutics, Inc..

Action: resigned as Chair
Role: Director

Exact text from the filing

Bruce Downey resigned as Chair of the Board, but will continue to serve as a member of the Board

View on SEC.gov

C4 Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-24-027399

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.